Difference between revisions of "Coltuximab ravtansine (SAR-3419)"
Jump to navigation
Jump to search
m |
|||
Line 14: | Line 14: | ||
[[Category:Antibody-drug conjugates]] | [[Category:Antibody-drug conjugates]] | ||
[[Category:Anti-CD19 antibodies]] | [[Category:Anti-CD19 antibodies]] | ||
+ | [[Category:Microtubule inhibitors]] | ||
[[Category:Diffuse large B-cell lymphoma medications]] | [[Category:Diffuse large B-cell lymphoma medications]] | ||
[[Category:Investigational]] | [[Category:Investigational]] |
Revision as of 14:41, 14 December 2014
Mechanism of action
Antibody-drug conjugate
Preliminary studies
Diffuse large B-cell lymphoma
- Abstract: B. Coiffier, V. Ribrag, J. Dupuis, H. Tilly, C. Haioun, F. Morschhauser, T. Lamy, C. Copie-Bergman, O. Brehar, R. Houot, J. M. Lambert, R. Morarui-Zamfir. Phase I/II study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered weekly to patients (pts) with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL). J Clin Oncol 29: 2011 (suppl; abstr 8017) link to original abstract